Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 89,433 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 89,433 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $91.86, for a total value of $8,215,315.38. Following the completion of the sale, the chief executive officer directly owned 869,881 shares of the company’s stock, valued at approximately $79,907,268.66. This trade represents a 9.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 2.7%

Shares of KNSA stock opened at $93.29 on Wednesday. The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1-year low of $37.02 and a 1-year high of $98.48. The stock’s fifty day simple moving average is $79.67 and its 200-day simple moving average is $60.56.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on KNSA shares. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, Canaccord Genuity Group increased their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Institutional Trading of Kiniksa Pharmaceuticals International

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Kiniksa Pharmaceuticals International by 213.5% during the 1st quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after purchasing an additional 327,595 shares in the last quarter. Spruce Street Capital LP raised its stake in shares of Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after purchasing an additional 326,081 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after buying an additional 251,578 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.